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Objectives. Physical activity (PA) is a preventive
strategy for cardiovascular disease and for managing
cardiovascular risk factors. There is little informa-
tion on the effectiveness of PA for the prevention
of cardiovascular outcomes once cardiovascular dis-
ease is present. Thus, we studied the relationship
between PA at baseline and cardiovascular events in
a high-risk population.
Design. A prespecified analyses of observational data
in a prospective, randomized hypertension study.
Setting. Losartan Intervention For Endpoint reduction
in hypertension (LIFE) study
Subjects. Hypertension and left ventricular hypertro-
phy (LVH) (n ¼ 9193).
Interventions. Losartan versus atenolol.
Main outcome measures. Reported level of PA: never
exercise, exercise £30 min twice per week, or exer-
cise >30 min twice per week at baseline and after a
mean of 4.8 years of treatment with losartan- versus
atenolol-based therapy. Risk reductions were calcula-
ted by level of PA for the primary composite end-
point and its components cardiovascular death, stroke
and myocardial infarction, and also all-cause mortality
and new-onset diabetes.
Results. A modest level of PA (>30 min twice per
week) was associated with significant reductions in
risk for the primary composite end-point [adjusted
hazard ratio (aHR) 0.70, P < 0.001) and its compo-
nents, all-cause mortality (aHR 0.65, P < 0.001), and
new-onset diabetes (aHR 0.66, P < 0.001).
Conclusion. A modest level of self-reported PA
(>30 min twice per week) in patients with hyperten-
sion and LVH in the LIFE study was associated with
significant reductions in risk for the primary compos-
ite end-point and its components of cardiovascular
death, stroke, and myocardial infarction, all-cause
mortality, and new-onset diabetes.
Keywords: atenolol, cardiovascular risk, exercise, LIFE
study, losartan, physical activity, type 2 diabetes.
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Introduction
The 1.5- to 2.4-fold increase in relative risk for coron-
ary heart disease associated with physical inactivity is
comparable to the risks associated with hypercholester-
olaemia, hypertension or smoking [1]. The estimated
costs of diseases associated with physical inactivity in
the United States are $76 billion annually [2]. Physical
activity (PA) is an accepted preventive approach for
cardiovascular disease and for managing selected car-
diovascular risk factors [3]. In previous studies, groups
with the lowest levels of PA, assessed by various
methods, were at greatest risk for cardiovascular dis-
ease [4–16]. However, once cardiovascular disease is
present, there is little information on the effectiveness
of PA for the prevention of cardiovascular outcomes.
To our knowledge, there are no data in the literature
from patients with hypertensive left ventricular hyper-
trophy (LVH) that relate PA to cardiovascular morbid-
ity/mortality. The Losartan Intervention For Endpoint
reduction in hypertension (LIFE) study provided one
of the first opportunities to study the relationships
between PA at baseline and cardiovascular outcomes
and new-onset diabetes in a large, well-conducted end-
point trial that enrolled patients with significant cardio-
vascular pathology.
Methods
The LIFE study was a prospective, multinational, dou-
ble-blind, randomized clinical trial that examined the
effects of losartan- compared with atenolol-based anti-
hypertensive treatment in 9193 patients with hyperten-
sion and electrocardiographic (ECG) LVH. The study
design, patient characteristics and results have been
published [17–19]. In short, patients aged 55–80 years
with ECG-LVH and with trough diastolic blood pres-
sure 95–115 mmHg and/or systolic blood pressure
160–200 mmHg after 2 weeks of placebo treatment
were eligible for participation in the study. Patients with
medical conditions requiring specific treatment with an
angiotensin-converting enzyme inhibitor, angiotensin
receptor blocker or beta-blocker were excluded from
the study, as were patients with history of stroke or
myocardial infarction within 6 months prior to the start
of the study or with left ventricular ejection fraction of
40% or less. Eligible patients (n ¼ 9193) were rand-
omized to losartan or atenolol and matching placebo.
The titration scheme was as follows: step 1, study drug
50 mg; step 2, study drug 50 mg plus hydrochlorothi-
azide (HCTZ) 12.5 mg; step 3, study drug 100 mg plus
HCTZ 12.5 mg; step 4, study drug 100 mg plus HCTZ
‡25 mg or addition of other antihypertensive agents
(excluding angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers or beta-blockers). Target
blood pressure was less than 140/90 mmHg. Patients
were included between June 1995 and April 1997 and
followed for a mean of 4.8 years.
The primary end-point was a composite of cardiovas-
cular death, nonfatal and fatal stroke, and nonfatal
and fatal myocardial infarction. All end-points were
adjudicated by an expert end-point classification com-
mittee. New-onset diabetes was assessed using WHO
criteria [20] in the 7998 patients who did not have
diabetes at baseline [21]. Quality of life was assessed
using a visual analogue scale on which patients
responded to the following prompt: ‘Below is a scale
from 0 to 100. On this scale, 100 is equivalent to the
best imaginable health state and 0 is the worst imagi-
nable health state. Please mark with an X where on
the scale you would place your present health state’.
Patients reported their level of PA at baseline and at
the end of follow-up as (i) never exercise, (ii) exercise
£30 min twice per week or (iii) exercise >30 min
twice per week. Patients were instructed to select one
of these categories that best described their exercise
habits. Mild (e.g. walking) or more strenuous exercise
was applicable. In the present analyses, data were
stratified according to these three groups of exercise
level.
All patients provided written informed consent, and
the protocol was approved by all relevant ethical
review committees.
Data management and analysis were performed using
SAS version 8 (Cary, NC, USA) software. Events
were analysed using the intent-to-treat approach.
Hazard ratios (HRs) for outcomes were assessed
using Cox regression analysis with and without
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adjustment for baseline current smoking (yes/no),
alcohol intake (yes/no), gender, age and race (white,
black and other), degree of LVH by Cornell voltage-
duration product and Sokolow-Lyon criteria (meas-
ured as continuous variables), and the Framingham
risk score [age, gender, total and high-density lipo-
protein (HDL) cholesterol, systolic blood pressure,
smoking, diabetes and LVH] [22]. The never-exercise
group was assigned an HR of 1. Kaplan–Meier
curves were generated for the primary composite
end-point and its components and depict unadjusted
rates. All tests were performed at two-sided 5%
significance levels.
Results
Of the 9185 patients with PA data available at base-
line, 51.8% exercised >30 min twice per week,
whilst 26.2% exercised £30 min twice per week and
22.0% never exercised (Table 1). The baseline char-
acteristics amongst the PA groups are shown in
Table 1. There were significantly higher proportions
of women, smokers, obese patients, and patients with
diabetes and signs of reduced renal function at lower
PA levels. Moreover, patients who did not exercise
had a history of significantly more cardiovascular
disease. There were significant trends to higher qual-
ity-of-life score and lower heart rate with higher PA
level (Table 1). The groups had comparable values
for Framingham risk score. Levels of serum uric
acid, sodium, potassium and urine creatinine, and
number of subjects with a medical history of periph-
eral vascular disease, atrial fibrillation or isolated
systolic hypertension (data not shown) did not differ
amongst groups.
Study drug distribution (data not shown) was similar
amongst the PA groups.
The reductions in blood pressure and heart rate were
clinically similar amongst the PA groups (systolic
blood pressure reduced 29–31 mmHg, diastolic blood
pressure 16–17 mmHg and heart rate 5 beats per
minute). The concomitant use of aspirin (21% in all
groups) or statins (5.8–6.9%) were not statistically
different amongst the PA groups.
The unadjusted and adjusted HR (Table 2) and Ka-
plan–Meier curves (Fig. 1) illustrate that patients exer-
cising >30 min twice per week experienced
significantly lower rates of the primary composite
end-point and its components of cardiovascular death,
stroke and myocardial infarction (P for myocardial
infarction ¼ 0.037 unadjusted; P ¼ 0.068 adjusted)
compared with those who never exercise. The risk for
cardiovascular death (P ¼ 0.017 unadjusted;
P ¼ 0.062 adjusted) and all-cause mortality
(P ¼ 0.013 unadjusted; P ¼ 0.085 adjusted) tended
to be intermediate in the £30 min twice per week
group compared with the never-exercise group. Risks
for stroke and the primary composite end-point were
not significantly different between the £30 min twice
per week and never-exercise groups in the unadjusted
and adjusted analyses. By subtracting cardiovascular
deaths from all-cause deaths, there was a modest but
not significant (P ¼ 0.28) trend towards fewer non-
cardiovascular deaths with higher levels of exercise.
Analyses additionally adjusted for available baseline
body mass index, serum creatinine, urinary albumin/
creatinine ratio and cardiovascular disease data (22.8–
28.6% of the subjects as specified in Table 1) were
consistent with those described above. A separate
gender analyses (Table 2a,b) showed the same trend
as described above with lower end-point rates
amongst the physically active subjects. However, the
absolute end-point rate per 1000 years of follow-up
was clearly higher amongst the males compared with
the females.
The risk of new-onset diabetes was decreased by 36%
(P < 0.001) in the patients who exercised >30 min
twice per week compared with the patients who never
exercised (Table 3), and was similar and consistent
after additional adjustments for available baseline
body mass index, serum creatinine, urinary albumin/
creatinine ratio and cardiovascular disease data. The
risk reduction was not significantly different between
the two treatment groups (data not shown). The risk
reduction was not significant for the £30 min twice
per week compared with the never-exercise group. A
separate gender analyses (Table 3a,b) showed a trend
similar to that described above with higher absolute
event rates amongst males compared with females.
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(n ¼ 4758) P-value
Characteristic
Age, years 67.61 (7.30) 67.13 (7.11) 66.57 (6.80) <0.001
Female, n (%) 1260 (62.4) 1350 (56.1) 2351 (49.4) <0.001
Race, n (%)
White 1737 (86.0) 2214 (92.0) 4546 (95.5) <0.001
Black 222 (11.0) 147 (6.1) 162 (3.4)
Other 61 (3.0) 46 (1.9) 50 (1.1)
Smoking status, n (%)
Never 975 (48.3) 1247 (51.8) 2432 (51.1) <0.001
Ex-smoker 584 (28.9) 779 (32.4%) 1668 (35.1)
1–10 day)1 249 (12.3) 222 (9.2) 409 (8.6)
11–20 day)1 140 (6.9) 124 (5.2) 171 (3.6)
>20 day)1 70 (3.5) 35 (1.5) 77 (1.6)
Alcohol intake
None 1119 (55.4) 1101 (45.7) 1994 (41.9) <0.001
1–4 week)1 651 (32.2) 983 (40.8) 1965 (41.3)
5–10 week)1 177 (8.8) 230 (9.6) 590 (12.4)
>10 week)1 73 (3.6) 93 (3.9) 205 (4.3)
Quality of life 70.75 (18.33) 73.82 (17.34) 77.63 (15.96) <0.001
Systolic blood pressure, mmHg 175.79 (14.41) 173.96 (14.10) 174.07 (14.31) <0.001
Diastolic blood pressure, mmHg 97.71 (9.42) 97.70 (8.76) 97.87 (8.70) 0.673
Category
Body mass index, kg m)2 29.11 (5.59) 28.32 (4.94) 27.36 (4.20) <0.001
Heart rate, beats min)1 76.05 (11.62) 74.26 (10.81) 72.63 (10.87) <0.001
Cornell product mm · ms 2864 (1007) 2864 (1068) 2786 (1024) 0.001
Sokolow-Lyon, mm 29.01 (10.79) 29.83 (10.26) 30.49 (10.19) <0.001
Framingham risk score 22.58 (9.36) 22.49 (9.53) 22.26 (9.40) 0.357
Medical history, n (%)
Cardiovascular disease 578 (28.6) 644 (26.8) 1084 (22.8) <0.001
Coronary heart disease 377 (18.7) 413 (17.2) 678 (14.2) <0.001
Cerebrovascular disease 200 (9.9) 207 (8.6) 321 (6.7) <0.001
Heart failure 59 (2.9) 58 (2.4) 49 (1.0) <0.001
Diabetes 360 (17.8) 324 (13.5) 509 (10.7) <0.001
Chronic obstructive pulmonary disease 118 (5.8) 105 (4.4) 161 (3.4) <0.001
Haemoglobin, g L)1 140.90 (12.91) 142.60 (12.44) 142.98 (11.43) <0.001
Serum creatinine, l mol L)1 89.36 (22.41) 87.21 (21.30) 85.76 (18.45) <0.001
ALAT, lkat L)1 0.42 (0.29) 0.46 (0.34) 0.47 (0.42) <0.001
Serum glucose, mmol L)1 6.27 (2.52) 6.10 (2.20) 5.88 (2.02) <0.001
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(n ¼ 4758) P-value
Total cholesterol, mmol L)1 6.01 (1.15) 6.05 (1.11) 6.05 (1.12) 0.425
HDL cholesterol, mmol L)1 1.47 (0.43) 1.47 (0.43) 1.52 (0.44) <0.001
Urine albumin (median), mmol L)1 15.00 12.00 9.00 <0.001
Urine albumin/creatinine (median), mmol g)1 1.75 1.38 1.10 <0.001
ALAT, alanine aminotransferase; HDL, high-density lipoprotein. Values are mean (SD) unless otherwise noted. Categorical variables were
assessed with a chi-square test. Continuous variables were assessed with anova, except for urine albumin and urine albumin/creatinine, which
were assessed with a test of medians. Quality of life index was measured on a visual analogue scale from 0 to 100, where 0 was the worst and
100 was the best quality of life.









Never 294/2020 (14.6) 32.5 – – – –
£30 min twice/week 330/2407 (13.7) 29.9 0.92 (0.79–1.08) 0.301 0.95 (0.81–1.12) 0.536
>30 min twice/week 472/4758 (9.9) 21.2 0.65 (0.56–0.75) <0.001 0.70 (0.60–0.81) <0.001
Cardiovascular death
Never 147/2020 (7.3) 15.6 – – – –
£30 min twice/week 136/2407 (5.7) 11.8 0.75 (0.60–0.95) 0.017 0.80 (0.63–1.01) 0.062
>30 min twice/week 155/4758 (3.3) 6.7 0.43 (0.34–0.54) <0.001 0.49 (0.39–0.62) <0.001
Stroke
Never 137/2020 (6.8) 15.1 – – – –
£30 min twice/week 167/2407 (6.9) 15.0 0.99 (0.79–1.25) 0.959 1.04 (0.82–1.30) 0.768
>30 min twice/week 237/4758 (5.0) 10.5 0.70 (0.57–0.86) 0.001 0.77 (0.62–0.96) 0.019
Myocardial infarction
Never 93/2020 (4.6) 10.1 – – – –
£30 min twice/week 117/2407 (4.9) 10.4 1.02 (0.78–1.34) 0.878 1.03 (0.79–1.36) 0.812
>30 min twice/week 176/4758 (3.7) 7.8 0.77 (0.60–0.98) 0.037 0.79 (0.61–1.02) 0.068
All-cause mortality
Never 241/2020 (11.9) 25.5 – – – –
£30 min twice/week 236/2407 (9.8) 20.4 0.80 (0.67–0.95) 0.013 0.85 (0.71–1.02) 0.085
>30 min twice/week 337/4758 (7.1) 14.6 0.57 (0.48–0.67) <0.001 0.65 (0.55–0.77) <0.001
(a) Females
Primary composite end-point
Never 155/1260 (12.3) 26.9 – – – –
£30 min twice/week 153/1350 (11.3) 13.3 0.90 (0.72–1.12) 0.339 1.05 (0.84–1.32) 0.667
>30 min twice/week 168/2351 (7.1) 14.9 0.55 (0.44–0.69) <0.001 0.73 (0.59–0.92) 0.006
Cardiovascular death
Never 70/1260 (5.6) 11.7 – – – –
£30 min twice/week 67/1350 (5.0) 10.2 0.87 (0.62–1.22) 0.416 1.029 (0.73–1.44) 0.871
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The distribution of patients amongst the PA categories
at baseline and at the end of follow-up was similar in
the losartan and atenolol treatment groups (data not
shown). There were no interactions between treatment
and exercise for the primary composite end-point or
its components. The reported level of muscular side
effects was low (data not shown) and not different








>30 min twice/week 55/2351 (2.3) 4.8 0.41 (0.28–0.58) <0.001 0.55 (0.38–0.79) 0.001
Stroke
Never 81/1260 (6.4) 15.1 – – – –
£30 min twice/week 85/1350 (6.3) 15.0 0.95 (0.70–1.29) 0.741 1.12 (0.82–1.52) 0.470
>30 min twice/week 97/2351 (4.1) 10.5 0.61 (0.46–0.82) 0.001 0.83 (0.61–1.12) 0.222
Myocardial infarction
Never 48/1260 (3.8) 8.2 – – – –
£30 min twice/week 54/1350 (4.0) 8.4 1.02 (0.69–1.51) 0.920 1.16 (0.78–1.71) 0.467
>30 min twice/week 54/2351 (2.3) 4.7 0.58 (0.39–0.85) 0.0056 0.731 (0.49–1.09) 0.125
All-cause mortality
Never 124/1260 (9.8) 20.7 – – – –
£30 min twice/week 111/1350 (8.2) 16.9 0.81 (0.63–1.05) 0.114 0.95 (0.74–1.24) 0.718
>30 min twice/week 131/2351 (5.6) 11.3 0.54 (0.43–0.69) <0.001 0.72 (0.56–0.92) 0.010
(b) Males
Primary composite end-point
Never 139/760 (18.3) 42.3 – – – –
£30 min twice/week 177/1057 (16.7) 37.7 0.89 (0.71–1.11) 0.3141 0.90 (0.72–1.13) 0.377
>30 min twice/week 304/2407 (12.6) 27.6 0.65 (0.54–0.80) <0.001 0.71 (0.58–0.87) 0.001
Cardiovascular death
Never 77/760 (10.1) 22.3 – – – –
£30 min twice/week 69/1057 (6.5) 13.8 0.62 (0.45–0.86) 0.004 0.65 (0.47–0.90) 0.010
>30 min twice/week 100/2407 (4.2) 8.7 0.39 (0.29–0.52) <.001 0.45 (0.33–0.61) <0.001
Stroke
Never 56/760 (7.4) 16.9 – – – –
£30 min twice/week 82/1057 (7.8) 17.2 1.02 (0.73–1.43) 0.906 0.99 (0.70–1.39) 0.942
>30 min twice/week 140/2407 (5.8) 12.5 0.74 (0.54–1.01) 0.059 0.76 (0.56–1.05) 0.094
Myocardial infarction
Never 45/760 (5.9) 13.5 – – – –
£30 min twice/week 63/1057 (6.0) 13.0 0.97 (0.66–1.42) 0.857 0.99 (0.68–1.46) 0.973
>30 min twice/week 122/2407 (5.1) 10.8 0.80 (0.57–1.13) 0.208 0.86 (.61–1.23) 0.413
All-cause mortality
Never 117/760 (15.4) 33.9 – – – –
£30 min twice/week 125/1057 (11.8) 25.0 0.74 (0.57–0.95) 0.018 0.77 (0.60–1.00) 0.049
>30 min twice/week 206/2407 (8.6) 17.9 0.53 (0.42–0.66) <0.001 0.60 (0.48–0.76) <0.001
CI, confidence interval; HR, hazard ratio. Rate is per 1000 years of patient follow-up. The never-exercise group was designated an HR of 1.
Adjusted HRs are adjusted for baseline age, gender, current smoking (yes/no), alcohol use (yes/no), race (white, black, other), degree of left
ventricular hypertrophy and Framingham risk score.
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Discussion
Our data suggest that a modest level of PA (>30 min
twice per week) in patients with hypertension and
LVH in the LIFE study was associated with signifi-
cant reductions in risks for the primary composite
end-point and its components of cardiovascular death,
stroke, and myocardial infarction, and also all-cause
mortality and new-onset diabetes.
Although it is accepted that PA reduces risks for
cardiovascular events and new-onset diabetes, agree-
ment about the level of PA (frequency, intensity,
duration) has not been established because study
results of the effects of PA for hypertension, coron-
ary heart disease, stroke, and cardiovascular and all-
cause mortality have been inconsistent [4–9, 23–35].
An important finding in this study is the substantial
benefit demonstrated with very modest PA. The
American Heart Association [3] and the American
College of Sports Medicine [23] recommend 30 min
or more of moderate-intensity primarily aerobic PA
on most (preferably all) days of the week for redu-
cing the risk associated with hypertension. Although
we do not know the median activity level in our
PA categories, the level of PA that was found to
Primary composite endpoint 
2020 1928 1846 1768 1698   652 Never 
2407 2310 2228 2149 2061   885 ≤  30 
4758 4625 4507 4386 4251 1782 
































≤  30 min., 2 times/wk  HR 0.92 (95% CI 0.79-1.08) 
> 30 min., 2 times/wk  HR 0.65 (95% CI 0.56-0.75) 
Cardiovascular death 
2020 1973 1918 1859 1810   704 Never 
2407 2364 2319 2262 2218   967 ≤  30 
4758 4698 4642 4571 4485 1920 > 30 


























≤  30 min., 2 times/wk  HR 0.75 (95% CI 0.60-0.95) 
> 30 min., 2 times/wk  HR 0.43 (95% CI 0.34-0.54) 
Stroke 
2020 1929 1851 1778 1716   662 Never 
2407 2318 2246 2177 2109   909 ≤  30 
4758 4634 4533 4427 4320 1824 


























≤  30 min., 2 times/wk  HR 0.99 (95% CI 0.79-1.25) 
> 30 min., 2 times/wk  HR 0.70 (95% CI 0.57-0.86) 
Myocardial infarction 
2020 1940 1866 1795 1735   683Never 
2407 2337 2274 2202 2140   936≤  30 
4758 4656 4574 4483 4370 1851


























≤  30 min., 2 times/wk  HR 1.02 (95% CI 0.78-1.34) 
> 30 min., 2 times/wk  HR 0.77 (95% CI 0.60-0.98) 
> 30 
> 30 > 30 
(a) (b) 
(c) (d) 
Fig. 1 Kaplan–Meier curves: (a) primary composite end-point; (b) cardiovascular death; (c) stroke; (d) myocardial infarction.
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result in best reduction in risk for cardiovascular
events in our analysis can be assumed to be lower
than recommended.
Several studies have evaluated the effect of PA in
presumably healthy subjects [4, 7, 10, 15, 24] or
looked into intermediate end-points [3, 24, 25, 36–
38]. In contrast, the present analysis was conducted
in older patients with significant cardiovascular
pathology. Because of the severity of hypertension in
this population, and the presence of LVH and other
concurrent risk factors, major cardiovascular events
occurred in the LIFE study at rates that were sub-
stantially higher than most studies that have exam-
ined the preventive impact of PA. Despite similar
study drug dosages, heart rates and blood pressure
control amongst the three PA categories in this ana-
lysis, patients in the highest PA level group
(>30 min twice per week) experienced significantly
lower rates of events compared with the lowest
(never-exercise) and middle (£30 min twice per
week) groups. The level of PA in the three groups
did not modify blood pressure or heart rate responses
to intensive antihypertensive treatment. Moreover,
there were no interactions between treatment and
exercise. Thus, randomization to a beta-blocker did
not cause a change in exercise level when compared
with the losartan group.
Several studies looking into the effect of PA have been
performed in men only [4, 6, 7, 9–11, 13, 16, 27, 31,
33, 35, 39]. Low physical fitness has been associated
with higher levels of all-cause mortality in women [14].
In the present analyses, the protective effect of exercise
was present both in men and women, both for cardio-
vascular end-points, all-cause mortality and new-onset
diabetes. However, the differences were not statistically
significant for all subgroups (stroke and myocardial
infarction), most probably due to the lower number of
subjects and thus statistical power in these sub-analy-
ses. The absolute end-point rate per 1000 years of fol-
low-up, however, was clearly higher amongst males
than females.
Regular aerobic exercise reduces the risk of new-onset
diabetes [36–38, 40, 41], and exercise training has been
shown to improve insulin action and glucose tolerance
in patients with impaired glucose tolerance and type 2
diabetes [37]. There are reduced risks for cardiovascu-
lar disease, cardiovascular death and all-cause death in
men with type 2 diabetes who exercised [39]. In the
present analyses, we also observed a similar pattern in a






Never 19.2 142/1660 (8.6) –
£30 min twice/week 18.3 174/2083 (8.4) 0.95 (0.76–1.19) 0.670 0.95 (0.76–1.19) 0.676
>30 min twice/week 12.3 246/4249 (5.8) 0.64 (0.52–0.79) <0.001 0.66 (0.53–0.81) <0.001
(a) Females
Never 16.6 79/1044 (7.6) –
£30 min twice/week 16.8 91/1167 (7.8) 1.01 (0.75–1.36) 0.960 1.05 (0.77–1.43) 0.751
>30 min twice/week 11.4 115/2116 (5.4) 0.68 (0.51–0.91) 0.009 0.74 (0.55–0.99) 0.043
(b) Males
Never 23.9 63/616 (10.2) –
£30 min twice/week 20.4 83/916 (9.1) 0.85 (0.61–1.18) 0.338 0.88 (0.63–1.22) 0.434
>30 min twice/week 13.2 131/2133 (6.1) 0.55 (0.41–0.74) <0.001 0.60 (0.44–0.81) 0.001
CI, confidence interval; HR, hazard ratio; n/M ¼ number of patients with new-onset diabetes/number of patients in category. Rate is per
1000 years of patient follow-up. Patients with diabetes at baseline were excluded. The never-exercise group was designated an HR of 1. Adjus-
ted HRs are adjusted for baseline age, gender, current smoking (yes/no), alcohol use (yes/no), race (white, black, other), degree of left ventric-
ular hypertrophy and Framingham risk score.
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hypertensive high-risk population. The difference was
still significant after adjustment for body mass index
and other baseline variables.
There are some limitations to this analysis. In contrast
to most studies looking into the effect of PA, the present
analysis was based on self-reported activity level and
not objectively measured fitness. We are unable to
quantify the level (e.g. METS) or type of PA reported
in this study. The ranges within the PA categories, espe-
cially the highest level, may be quite broad; however,
we do not expect that this population of patients aged
55–80 years with hypertension and LVH would have
exercised to an extent that would have significantly
increased the median exercise level in the >30 min
twice a week group. Moreover, patients may have been
self-sorted based on their underlying health and func-
tion so that higher exercise may not have been the cause
of the observed benefits, but may have been a marker
of better health. We are unable to assess whether un-
measured behavioural covariates may have contributed
to our findings. A strength of our findings is that adjust-
ing the analysis for baseline smoking status, alcohol
consumption, gender, age, LVH and Framingham risk
score did not influence the statistical significance for
the primary composite end-point. Importantly, this was
a large, well-conducted end-point trial that included
careful adjudication of each reported end-point.
A modest level of self-reported PA (>30 min twice
per week) in patients with hypertension and LVH
in the LIFE study was associated with significant
reductions in risk for the primary composite end-
point and its components of cardiovascular death,
stroke and myocardial infarction, and also all-cause
mortality and new-onset diabetes.
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